With 4.87 million shares changed hands, the volume of the stock remained lighter than its average volume of 6.04 million shares. During the session, the Biotechnology company that operates in wider Healthcare sector, reached to the highest price of $9.33 whereas the lowest price it dropped to was $9.05. The 52-week range on ARDX shows that it touched its highest point at $10.13 and its lowest point at $3.16 during that stretch. It currently has a 1-year price target of $13.83. Beta for the stock currently stands at 0.82.
Price Performance and Earnings:
Stock performance is one of the indicators that investors use to determine whether they will profit from a stock. The price performance of ARDX was up-trending over the past week, with a rise of 45.47%, but this was up by 27.19% over a month. Three-month performance surged to 2.08% while six-month performance rose 131.59%. The stock gained 101.95% in the past year, while it has gained 50.16% so far this year. A look at the trailing 12-month EPS for ARDX yields -0.29 with Next year EPS estimates of 0.12. For the next quarter, that number is -0.11. This implies an EPS growth rate of -22.55% for this year and 133.03% for next year. EPS is expected to grow by 30.00% annually over the next five years; however, over the past five years, the company experienced an annual growth rate of 28.61%.
Float and Shares Shorts:
At present, 232.45 million ARDX shares are outstanding with a float of 224.94 million shares on hand for trading. On 2024-04-15, short shares totaled 33.93 million, which was 1449.9999999999998 higher than short shares on 1710460800. In addition to Mr. Michael G. Raab as the firm’s President, CEO & Director, Ms. Elizabeth A. Grammer Esq. serves as its Chief Legal & Administrative Officer and Secretary.
Institutional Ownership:
Through their ownership of 0.60681 of ARDX’s outstanding shares, institutional investors have minority control over the company.
An Overview of Recent Financials:
Understanding a company as a customer does not mean you will understand it as an investor. The wise investor uses quantitative research to analyze metrics such as revenue, net income, and earnings. In its fiscal quarter reported on 2024-03-31, ARDX reported revenue of $46023000.0 and operating income of -$24678000.0. The EBITDA in the recently reported quarter was -$21904000.0 and diluted EPS was -$0.11.
Analysts Ratings:
Reading analyst opinions is an effective way to decide where to invest, and there are several opinions available for ARDX since 0 analysts follow the stock currently. In the same way, a target price assigned to a stock can also reveal much about its potential.
